# Vuzix Corporation

Type: Company (VUZI)

Source: GetYourBrief — https://getyourbrief.com/entity/vuzix-corporation
Canonical HTML page: https://getyourbrief.com/entity/vuzix-corporation

## Timeline

- **2026-12-22**: Lorundrostat PDUFA Date — Target date for FDA decision on Mineralys' lead product candidate.
- **2026-06-01**: Nektar Phase 3 Launch — Nektar plans first patient randomization for its Atopic Dermatitis program.
- **2026-03-12**: Mineralys NDA Acceptance — FDA accepts Mineralys' NDA for lorundrostat for uncontrolled hypertension.
- **2025-12-31**: EHang Record Deliveries — EHang closes Q4 with 100 eVTOL units delivered and first GAAP profit.
- **2025-12-01**: HeartBeam FDA Clearance — HeartBeam secures 510(k) clearance for 12-lead ECG synthesis software.

## Recent coverage (3 stories, network-wide)

### Biotech and Deep Tech Reach Critical Inflection Points in Q4 Earnings
2026-03-13 00:13:52 · Sector: startups · Sentiment: Positive · Impact: 7/10 · Sources: 15

The Q4 2025 earnings cycle marks a pivot toward commercial maturity for high-growth ventures, highlighted by Mineralys Therapeutics' FDA filing and EHang's first GAAP-profitable quarter. These results signal a de-risking phase for investors as pre-revenue startups transition into regulated, revenue-generating entities.
Full story: https://getstartupbrief.com/story/biotech-deep-tech-q4-2025-earnings-analysis

### EHang Hits Profitability Milestone as eVTOL and AR Sectors Scale for 2026
2026-03-13 00:09:12 · Sector: space · Sentiment: Positive · Impact: 7/10 · Sources: 15

EHang (EH) achieved its first quarterly GAAP profit on record eVTOL deliveries, signaling a commercial inflection point for Advanced Air Mobility. Simultaneously, Vuzix (VUZI) reported a 76% revenue surge in smart glasses and waveguide technology, underscoring robust demand for dual-use augmented reality systems.
Full story: https://getspacebrief.com/story/ehang-vuzix-q4-2025-earnings-analysis

### Mineralys and Vuzix Q4 2025: Clinical Milestones and AR Adoption in Focus
2026-03-12 23:32:16 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Mineralys (MLYS) and Vuzix (VUZI) reported Q4 2025 results, highlighting divergent but critical paths in healthcare innovation: the clinical validation of next-generation hypertension therapies and the operational scaling of augmented reality in surgical settings. While Mineralys focuses on pivotal trial readouts for lorundrostat, Vuzix is navigating a transition toward OEM and high-margin medical software solutions.
Full story: https://gethealthbrief.com/story/mineralys-vuzix-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.